Accelerating to better health
Rivus Pharmaceuticals, Inc. is dedicated to improving cardiometabolic health by advancing a new class of investigational medicines called controlled metabolic accelerators (CMAs). These oral small molecules are designed to reduce excess fat and treat a broad range of cardiometabolic diseases by safely leveraging the natural process of mitochondrial uncoupling. Activating this metabolic process results in fat-specific weight loss, preservation of muscle mass, reduction of liver and visceral fat, improved glycemic control and reductions in oxidative stress and inflammation. Rivus’ lead CMA, HU6, is in development to treat obesity and associated cardiometabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes. Rivus’ discovery platform which combines an uncoupling AI/ML classifier model trained on proprietary datasets has yielded additional CMA candidates for preclinical development in therapeutic areas with significant need.
Rivus Pharmaceuticals, Inc. is dedicated to improving cardiometabolic health by advancing a new class of investigational medicines called controlled metabolic accelerators (CMAs). These oral small molecules are designed to reduce excess fat and treat a broad range of cardiometabolic diseases by safely leveraging the natural process of mitochondrial uncoupling. Activating this metabolic process results in fat-specific weight loss, preservation of muscle mass, reduction of liver and visceral fat, improved glycemic control and reductions in oxidative stress and inflammation. Rivus’ lead CMA, HU6, is in development to treat obesity and associated cardiometabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes. Rivus’ discovery platform which combines an uncoupling AI/ML classifier model trained on proprietary datasets has yielded additional CMA candidates for preclinical development in therapeutic areas with significant need.
OUR SCIENCE
Addressing a primary driver of cardiometabolic disease: obesity
Nearly half of American adults are living with cardiometabolic diseases. While numerous factors contribute to these diseases, a common thread driving pathology is obesity, the result of excess fat in the body. Associated with an elevated risk of heart failure, type 2 diabetes, dyslipidemia, MASLD/MASH and other indications, obesity presents an opportunity to target a significant risk factor for cardiometabolic disease. Newer therapies support weight loss but may also reduce lean muscle mass, which can lead to weight regain and increased cardiovascular risk.
Harnessing a natural metabolic process for fat selective weight loss
Rivus’ Controlled Metabolic Accelerators (CMAs) are oral small molecules which are designed to reduce excess fat and treat a broad range of cardiometabolic diseases by safely leveraging the natural process of mitochondrial uncoupling. Mitochondrial uncoupling accounts for approximately 20-40% of caloric consumption and significantly contributes to basal metabolic rate. Rivus’ CMAs provide a novel, measured approach to activating this process, reducing fat throughout the body while preserving skeletal muscle mass.
Presented by Rivus CSO Shaharyar Khan, PhD
Harnessing a natural metabolic process for fat selective weight loss
Rivus’ Controlled Metabolic Accelerators (CMAs) are oral small molecules which are designed to reduce excess fat and treat a broad range of cardiometabolic diseases by safely leveraging the natural process of mitochondrial uncoupling. Mitochondrial uncoupling accounts for approximately 20-40% of caloric consumption and significantly contributes to basal metabolic rate. Rivus’ CMAs provide a novel, measured approach to activating this process, reducing fat throughout the body while preserving skeletal muscle mass.
Leveraging the powerhouse of the cell to achieve better health
By harnessing the natural mechanism of mitochondrial uncoupling, Rivus’ therapies accelerate metabolism with the aim of enabling healthy lives for millions.
IMPROVE CELLULAR METABOLISM
Controlled metabolic accelerators (CMAs) like HU6 are oral, small molecule therapies designed to improve cellular metabolism. CMAs harness a natural metabolic process in mitochondria, the powerhouse of cells, to increase the breakdown of fats and sugars and increase resting energy expenditure.
REDUCE FAT, PRESERVE MUSCLE
By increasing energy expenditure, CMAs decrease fat throughout the body while maintaining skeletal muscle mass. Muscle retention is critical to minimize fat regain and reduce cardiometabolic risk.
CLINICAL
OPPORTUNITY
In a Phase 2 clinical trial, HU6, a first-in-class CMA, was shown to improve disease markers of blood pressure, inflammation and glycemic control. CMAs are now being studied to treat obesity and its comorbidities for patients suffering from heart failure, MASLD/MASH and type 2 diabetes.
OUR PIPELINE
CMAs have the potential to provide well-tolerated, effective treatments that improve cardiometabolic health with applicability to a broad range of diseases.
Clinical research demonstrates the potential of Rivus’ lead candidate HU6, a first-in-class CMA, to address a broad range of cardiometabolic diseases by increasing fat selective weight loss and improving key markers of glycemic control and inflammation. Importantly, no loss of lean muscle mass has been observed, suggesting reduced risk of weight regain and reduced cardiovascular risk.
For its lead program HU6, Rivus Pharmaceuticals has completed Phase 1 clinical studies and a Phase 2a metabolic study, which was published in The Lancet Gastroenterology & Hepatology. Building on data from the metabolic study, Rivus initiated a Phase 2a study in patients with obese heart failure with preserved ejection fraction (HFpEF) and a Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH). Rivus is expanding its pipeline of CMAs targeting diseases where the evidence for safe metabolic acceleration is strong and the therapeutic need is great.
RIVUS CONTROLLED METABOLIC ACCELERATOR PIPELINE
Target Indication |
Candidate/Target |
Preclinical |
Phase I |
Phase II |
Phase III |
|---|---|---|---|---|---|
|
Obese HFpEF, MASH, T2D, Obesity
|
HU6
ANT-Activator |
||||
|
Obesity, CVD
|
RV-002
ANT-Activator |
||||
|
Obesity
|
RV-003
GLP1R / ANT-Activator |
ANT-activator
ANT-activator
GLP1R / ANT-Activator
HFpEF – heart failure with preserved ejection fraction; MASH – metabolic dysfunction-associated steatohepatitis; T2D – type 2 diabetes; CVD – cardiovascular disease; ANT – adenine nucleotide translocase; GLP1R – glucagon-like peptide 1 receptor
Scientific Publications and Presentations
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
The Lancet Gastroenterology & Hepatology 2023
Noureddin, Mazen, et al.
A Novel Controlled Metabolic Accelerator for the Treatment of Obesity-Related HFpEF: Rationale and Design of the Phase 2a HuMAIN Trial
European Journal of Heart Failure 2024
Kitzman, W., Dalane, et al.
A Novel Controlled Metabolic Accelerator for the Treatment of Obesity-Related HFpEF: The HuMAIN-HFpEF Trial
Presented at the Heart Failure Society of America Annual Scientific Meeting 2024
Pandey, Ambarish, et al.
Relevant Literature
Mitochondrial Uncoupling and Weight Loss
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
Obesity 2021
Christoffersen, Berit, et al.
Implications of mitochondrial uncoupling in skeletal muscle in the development and treatment of obesity
The Federation of European Biochemical Societies Journal 2013
Thrush, Brianne A., et al.
Mitochondrial uncoupling as a target for drug development for the treatment of obesity
Obesity Reviews 2001
Harper, J. A., et al.
Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control
Journal of Cachexia, Sarcopenia and Muscle 2022
Dantas, Wagner S., et al.
Therapeutic Benefits of Mitochondrial Uncouplers beyond Weight Loss
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential
Journal of Medicinal Chemistry 2018
Childress, Elizabeth S., et al.
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
Molecular Metabolism 2021
Goedeke, Leigh, et Shulman, Gerald I.
Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
Science (AAAS) 2015
Perry, Rachel J., et al.
Neuroprotective Potential of Mild Uncoupling in Mitochondria. Pros and Cons
Brain Sciences 2021
Zorov, Dmitry B., et al.
Mitochondrial Dysfunction and Disease
Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis
Frontiers in Physiology 2022
Qu, Kai, et al.
Mitochondrial Dysfunction: The Hidden Player in the Pathogenesis of Atherosclerosis?
International Journal of Molecular Sciences 2023
Ciccarelli, Giovanni, et al.
Nitric oxide deficiency is a primary driver of hypertension
Biochemical Pharmacology 2022
Bryan, Nathan S.
Oxidative capacity in failing hearts
American Journal of Physiology 2003
Gong, Guangrong, et al.
Mitochondrial Function and Longevity
Further Support to the Uncoupling-to-Survive Theory: The Genetic Variation of Human UCP Genes Is Associated with Longevity
PLOS One 2011
Giuseppina, Rose, et al.
Cellular energetics and mitochondrial uncoupling in canine aging
GeroScience 2019
Nicholatos, Justin W., et al.
Mild mitochondrial uncoupling in mice affects energy metabolism, redox balance and longevity
Aging Cell 2008
Caldeira da Silva, Camille C., et al.
Mitochondrial Mechanics and Energy Metabolism
Use the Protonmotive Force: Mitochondrial Uncoupling and Reactive Oxygen Species
Journal of Molecular Biology 2018
Berry, Brandon J., et al.
Mitochondrial uncouplers induce proton leak by activating AAC and UCP1
Nature 2022
Bertholet, Ambre M., et al.
Increased substrate oxidation and mitochondrial uncoupling in skeletal muscle of endurance-trained individuals
Proceedings of the National Academy of Sciences of the United States of America 2008
Befroy, Douglas E., et al.
The Obesity Phenotype of HFpEF
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Circulation 2017
Obokata, Masaru, et al.
The HFpEF Obesity Phenotype: The Elephant in the Room
Journal of the American College of Cardiology 2016
Kitzman, Dalane W., et al.
CLINICAL TRIALS
For more information on any Rivus-sponsored clinical trials, please contact our clinical operations team at info@rivuspharma.com.
Expanded Access PolicyEXPANDED ACCESS TO INVESTIGATIONAL MEDICINES
At this time, Rivus Pharmaceuticals does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible. Clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
Our Team
The Rivus team is a group of forward-thinking scientists and proven biotech leaders deeply committed to the field of cardiometabolic health. Our team of experts is driven to provide patients and physicians with a new and highly effective solution to one of the most challenging issues in healthcare today.
Ian F. Smith currently serves as a senior advisor to Bain Capital Life Sciences. In addition to serving as the chairman of the board of Rivus, he is executive chairman of the board of Solid Biosciences, a public biotechnology company; a member of the board of Foghorn Therapeutics and Stoke Therapeutics, both public biotechnology companies; and a member of the board of Alkeus Pharmaceuticals and iVexSol Inc, both private biotechnology companies. He was formerly director and executive chair of the board of ViaCyte, Inc., a private biotechnology company that was acquired in fall 2022. From 2001 to 2019, Mr. Smith held the positions of executive vice president and chief operating officer and chief financial officer at Vertex Pharmaceuticals, a public biotechnology company. He received a B.A. with honors in accounting and finance from Manchester Metropolitan University in the UK.
Jayson Dallas is the Chief Executive Officer at Rivus. Prior to joining Rivus, he served on the Board of Directors at Arena Pharmaceuticals from February 2017 to March 22, when Arena was acquired by Pfizer. Dr. Dallas also served as President and Chief Executive Officer of Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, from June 2018 to October 2020, when Aimmune was acquired by Nestlé Health Science. Prior to joining Aimmune, he served as the first Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical, Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, since August 2015. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from January 2013 to July 2015. Before joining Roche, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Earlier in his career, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.
Jayson Dallas is the Chief Executive Officer at Rivus. Prior to joining Rivus, he served on the Board of Directors at Arena Pharmaceuticals from February 2017 to March 22, when Arena was acquired by Pfizer. Dr. Dallas also served as President and Chief Executive Officer of Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, from June 2018 to October 2020, when Aimmune was acquired by Nestlé Health Science. Prior to joining Aimmune, he served as the first Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical, Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, since August 2015. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from January 2013 to July 2015. Before joining Roche, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Earlier in his career, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.
Tom O’Neil is the chief financial officer at Rivus. He has more than 25 years of experience in the biopharmaceutical industry, from start-ups through large public companies, and has had roles in executive leadership, finance, investor relations, operations, strategy, business/corporate development and commercialization. Prior to Rivus, he served as chief financial officer for a number of biopharmaceutical companies, including Satsuma Pharmaceuticals, Protagonist Therapeutics, Arcadia Biosciences, and Sorbent Therapeutics. Earlier in his career, he was a consultant to Sorbent and a variety of life sciences and technology companies. Prior to that, he served as vice president of finance and administration at ChemGenex Pharmaceuticals Ltd., Cephalon and Nodality. He also served in finance and operations roles for medical device, technology and other services companies. Tom earned a B.A. in international relations from Pomona College and an MBA from UCLA Anderson Graduate School of Management.
Allen Cunningham is the Chief Operating Officer at Rivus. He brings more than twenty years of experience developing early-stage and venture-backed companies across a number of sectors, including biotechnology, information technology, and renewable energy. Allen has expertise in all aspects of early-stage company development, including operations management, intellectual property, product development, licensing and distribution, mergers and acquisition, and finance. Prior to Rivus, he co-founded and served as the CEO of Gencia Biotech. Allen graduated from the University of Virginia with a Bachelor of Arts in English.
Francesco De Rubertis is a co-founder and Partner at Medicxi since 2016. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Dr. De Rubertis serves on the boards of a number of private biotechnology companies, including Rivus Pharmaceuticals, Synox Therapeutics and Levicept. Dr. De Rubertis’s prior investments include CellZome, GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet, Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics, Parallele Biosciences, Profibrix and Versartis (NASDAQ:VSAR). Dr. De Rubertis received a B.A. in Genetics and Microbiology from the University of Pavia (Italy) and a PhD in Molecular Biology from the University of Geneva (Switzerland) after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva (Switzerland).
Robert Schott is the Chief Medical Officer at Rivus. He joined the company from Nutcracker Therapeutics, where he served as Chief Medical Officer, focusing on mRNA therapeutics. Before that, he was a Senior Vice President and Head of Development at Sangamo Therapeutics, focusing on gene and cell therapies in rare diseases. Dr. Schott was at Eli Lilly for seven years, where he served as Chief Medical Officer for Chorus, the autonomous early-phase drug development group inside of Lilly. There, he oversaw the clinical development strategy across diverse indications and platforms. Dr. Schott earned an M.D. from the University of Michigan Medical School and an M.P.H. in epidemiology from the University of Michigan School of Public Health. He completed an internal medicine residency at the University of Michigan Hospitals and a fellowship in cardiology at Massachusetts General Hospital.
Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and currently serves as a Board Director for multiple private and public biotech companies. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt Signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.
Erin Lavelle has more than 25 years of strategic and operational leadership experience in the biopharmaceutical industry. She most recently served as chief operating officer (COO) and chief financial officer (CFO) at ProfoundBio, where she led a $112 million Series B and initial public offering (IPO) preparation and negotiated a $1.9 billion sale to Genmab in 2024. Prior to her leadership roles at ProfoundBio, she was the COO/CFO at Eliem Therapeutics, a biotechnology firm based in Seattle. She was instrumental in orchestrating Eliem’s IPO. Before Eliem, she was the COO of Alder Biopharmaceuticals, Inc., where she led the company’s $2.3 billion acquisition by H. Lundbeck A/S. Her extensive tenure in the biopharmaceutical sector also includes 15 years at Amgen, culminating as general manager of Amgen’s Taiwan affiliate. Prior to that leadership role, she was based in Hong Kong as an executive director for the Japan Asia-Pacific region, spearheading Commercial Excellence and Digital Health initiatives. Her earlier positions at Amgen involved executive leadership in Global Marketing, Global Commercial Finance, and Strategy & Corporate Development. Erin began her career as an investment banker in the healthcare group at Merrill Lynch & Co. She served on the boards of Neoleukin (NLTX) and Vitaeris, a private company located in Vancouver. She earned a B.A. in economics from Yale University.
Rick E Winningham is the Chairman and CEO of Theravance Biopharma, Inc., since July 2013 and June 2014, respectively, following his leadership at Theravance, Inc. (now Innoviva, Inc.) from 2001 to 2014. His career began at Bristol Myers Squibb and its predecessor Bristol Myers in 1986, where he held various U.S. and global management positions, culminating in his role as the President of the Oncology/Immunology/Oncology Therapeutics Network and President of Global Marketing, overseeing a range of therapeutic areas until 2001.
Beyond his executive roles, Mr. Winningham is currently a member of the board of directors for the Biotechnology Industry Organization, where he serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham was a director at the California Healthcare Institute (CHI) from November 2011 until its merger with Baybio in March 2015, creating the California Life Sciences Association (CLSA). He chaired CHI from January 2014 to March 2015, and then served on CLSA’s board, including as its chairman, from March 2015 to July 2023. He is currently a member of the board of directors of Jazz Pharmaceuticals plc. and served as a member of the board of directors of Retrotope Inc. from February 2021 until January 2022, and OncoMed Pharmaceuticals, Inc. from June 2015 until April 2019.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University.
Allen Cunningham is the Chief Operating Officer at Rivus. He brings more than twenty years of experience developing early-stage and venture-backed companies across a number of sectors, including biotechnology, information technology, and renewable energy. Allen has expertise in all aspects of early-stage company development, including operations management, intellectual property, product development, licensing and distribution, mergers and acquisition, and finance. Prior to Rivus, he co-founded and served as the CEO of Gencia Biotech. Allen graduated from the University of Virginia with a Bachelor of Arts in English.
Shaharyar Khan is Chief Scientific Officer at Rivus. An expert in mitochondrial biology and seasoned leader with more than two decades of experience managing multidisciplinary teams of talented mitochondrial biologists, computational and medicinal chemists, and clinicians. Shaharayar is dedicated to the pursuit of novel mitochondrial therapeutics. He co-founded Gencia Biotech where he also served as CSO. At Gencia, Shaharyar pioneered multiple drug discovery programs, including large and small molecules, aimed at harnessing the unique role of mitochondria in the maintenance of cellular health. Shaharyar earned his PhD in Neuroscience from the University of Virginia.
Shaharyar Khan is Chief Scientific Officer at Rivus. An expert in mitochondrial biology and seasoned leader with more than two decades of experience managing multidisciplinary teams of talented mitochondrial biologists, computational and medicinal chemists, and clinicians. Shaharayar is dedicated to the pursuit of novel mitochondrial therapeutics. He co-founded Gencia Biotech where he also served as CSO. At Gencia, Shaharyar pioneered multiple drug discovery programs, including large and small molecules, aimed at harnessing the unique role of mitochondria in the maintenance of cellular health. Shaharyar earned his PhD in Neuroscience from the University of Virginia.
Francisco Portell is the VP, Pharmaceutical Development at Rivus. With over 20 years of research experience in mitochondrial biology, Francisco has worked on multiple drug discovery programs involving both large and small molecules. As a co-founder of and Senior Scientist at Gencia, he led the biologics development program and partnering efforts with industry experts on bacterial genetics, fermentation, tangential flow filtration, chromatography and formulation. Prior to Gencia, Francisco worked at the University of Virginia Center for Neurodegeneration researching mitochondrial dysfunction in Alzheimer’s and Parkinson’s disease.
CAREERS
Rivus has offices in San Francisco, California and Charlottesville, Virginia and is seeking candidates to join our growing team as we expand our pipeline of controlled metabolic accelerators (CMAs).
CONTACT
hr@rivuspharma.com
NEWS
Learn more about Rivus and controlled metabolic accelerators (CMAs).
PRESS RELEASES
Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure
Rivus Pharmaceuticals to Present New Data from Phase 2a HuMAIN Trial of HU6 for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction at Heart Failure Society of America Annual Scientific Meeting 2024
Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O’Neil as Chief Financial Officer and Erin Lavelle as Director
Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial Rationale and Design in European Journal of Heart Failure
Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6
Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments
Phase 2a Study of HU6, Rivus Pharmaceuticals’ Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High BMI and Nonalcoholic Fatty Liver Disease
Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO
Rivus Pharmaceuticals to Present Results from a Phase 2a Trial Evaluating its Controlled Metabolic Accelerator, HU6, at the American Association for the Study of Liver Diseases (AASLD)
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardiometabolic Disorders
NEWS
PRESS RELEASES
Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants
NEWS
PRESS RELEASES
Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants
- Met primary endpoint (liver fat reduction), multiple secondary endpoints (whole body, visceral, subcutaneous fat loss)
- Significant fat selective weight loss while preserving muscle mass, without changes in diet or exercise
- Amplified weight and fat loss in patients with elevated HbA1c
- Improvement in key markers of insulin resistance and inflammation
- Well tolerated across all studied doses
HU6 leads a pipeline of first-in-class, orally administered Controlled Metabolic Accelerators (CMAs) that accelerate fat metabolism and treat the underlying cause of type 2 diabetes, HFpEF, NASH, and other cardiovascular and metabolic diseases
CHARLOTTESVILLE, Va., February 9, 2022 – Rivus Pharmaceuticals Inc., a biopharmaceutical company dedicated to improving cardio-metabolic health, today announced positive results from a Phase 2a clinical trial of HU6 in obese participants with elevated liver fat. In eight weeks, HU6 demonstrated significant reductions in liver, visceral, and total body fat while conserving skeletal muscle mass, leading to significant reductions in total body weight. Uniquely, the greatest reductions in weight and body fat were observed in patients who had high baseline HbA1c levels. Improvements were also observed in key metabolic parameters that drive the pathophysiology of type 2 diabetes, heart failure with preserved ejection fraction (HFpEF), and non-alcoholic steatohepatitis (NASH). HU6 was well tolerated across all studied doses.
“We are highly encouraged by the Phase 2a clinical data evaluating HU6 to improve cardio-metabolic health. In this a relatively short study of 8 weeks, HU6 was able to achieve meaningful results safely in a high percentage of responders. By reducing fat in the liver, and throughout the body, HU6 addresses the root cause of poor metabolic health and related diseases,” said Allen Cunningham, President and CEO of Rivus Pharmaceuticals.
HU6 Phase 2a Metabolic Trial Design and Results
The phase 2a metabolic trial of HU6 was a 61-day randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of three dose levels of HU6 (150 mg, 300mg, and 450 mg) in obese participants (body mass index 28 to 45 kg/m2) with elevated liver fat (greater than 8%). Eighty (80) participants between ages 28 and 65 were randomly assigned to one of three HU6 treatment groups or the matched placebo group, stratified and blocked for HbA1c levels of 5.7% or greater, and dosed once daily (fasting). Participants were instructed to not change behavior with regard to diet or exercise. The Phase 2a trial met primary (liver fat reduction by MRI-PDFF) and secondary (body weight and fat reduction by abdominal MRI) endpoints. Key results and observations include:
- Statistically significant (p<0.0001 by ANCOVA) reductions in liver fat at all three dose levels.
- Relative reductions in liver fat were 33%, 43%, and 40% corresponding to responder rates (>30% relative reduction) of 40%, 71% and 72% at low, mid and high doses, respectively, compared to placebo relative reduction in liver fat of 2% and responder rate of 5%.
- Body weight reduction almost exclusively from loss of fat, sparing skeletal muscle mass at all dosing levels at eight weeks, without change in diet or exercise behavior.
- Weight and fat loss showed a dose response with participants losing an average of 6 pounds (p<0.001, high dose vs. placebo).
- Participants with elevated HbA1c levels experienced greater weight and fat loss, losing an average of 10 pounds (p<0.0001, high dose vs. placebo).
- Fat loss was observed in hepatic, visceral, and subcutaneous compartments by MRI.
- Key cardiovascular and metabolic health indicators at all dosing levels including:
- Signficant dose dependent reduction in glycated albumin, an indicator of glucose control and insulin function.
- Significant dose dependent reduction in inflammation marker high sensitivity C-reactive protein (hsCRP), an important parameter of cardiovascular risk.
- HU6 was well-tolerated at all dose levels with excellent compliance. No Serious Adverse Events or deaths were reported. Intermittent diarrhea and transient flushing were the most commonly reported Treatment Emergent Adverse Events. The majority of these events were mild; one participant discontinued HU6 for diarrhea in the low dose arm while no participant discontinued at the high dose.
“This trial provides compelling proof of clinical concept for the efficacy and safety of mitochondrial uncoupling with HU6, our first in class CMA. HU6 pharmacology which selectively reduces fat and weight without appetite suppression is highly differentiated. Given early indications that this biology may reverse insulin resistance and systemic inflammation, we can now explore whether reducing visceral and organ fat can provide clinical benefits to patients across a host of cardiometabolic diseases,” said Shaharyar Khan, Ph.D., Rivus’ Chief Scientific Officer.
CMAs provide a new, measured approach to safely activating mitochondrial uncoupling, a process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs increase the oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction and the prevention of fat accumulation throughout the body.
In the first half of 2022, Rivus is continuing its HU6 clinical program with a Phase 2a study in heart failure with preserved ejection fracture (HFpEF) to be followed by Phase 2b studies in type 2 diabetes and non-alcoholic steatohepatitis (NASH).
About HU6
HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body.
About Rivus Pharmaceuticals
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease. Rivus’ first-in-class small molecule therapy, HU6, is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body’s natural processes to improve cellular metabolism and selectively oxidize fat. Rivus’ therapy presents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of cardio-metabolic conditions, including type 2 diabetes, heart failure with preserved ejection fraction (HFpEF), non-alcoholic steatohepatitis (NASH), and obesity. For more information, please visit rivuspharmadev.wpengine.com.
Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardiometabolic Diseases
NEWS
PRESS RELEASES
Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardiometabolic Diseases
HU6 was well tolerated and increased resting energy expenditure
Dose dependent weight loss and an improvement in metabolic parameters were also observed, despite the study not being powered to demonstrate them
Enrollment for a Phase 2a Metabolic Trial of HU6 has completed with topline data expected in Q1 2022
HU6 leads a pipeline of first-in-class Controlled Metabolic Accelerators (CMAs), designed to harness the body’s natural processes to improve cellular metabolism and treat underlying causes of poor metabolic health and cardiovascular disease
CHARLOTTESVILLE, Va. November 1, 2021 – Rivus Pharmaceuticals Inc., a biopharmaceutical company dedicated to improving cardio-metabolic health, today announced positive results from both single and multiple ascending dose portions of its Phase 1 clinical trial of HU6. HU6, a first-in-class, orally administered Controlled Metabolic Accelerator (CMA) therapy, demonstrated robust and sustained target engagement with no apparent safety signals. Additionally, sustained effects on key biological parameters relevant to cardio-metabolic diseases including type 2 diabetes, heart failure with preserved ejection fracture (HFpEF), non-alcoholic steatohepatitis (NASH), and severe hypertriglyceridemia (SHTG) were observed. HU6 was well-tolerated at all studied doses, and there were no serious adverse events. Participants dosed with HU6 demonstrated an increase in resting energy expenditure, dose dependent weight loss and improvements in metabolic parameters.
The HU6 Phase 1 program consisted of a double blind, placebo controlled, randomized single ascending dose (SAD) as well as a multiple ascending dose (MAD) trial. In the SAD portion of the program, 50 healthy volunteers received doses of HU6 ranging from 30 to 1400mg. In the MAD portion of the program, 24 subjects with high BMI (35-45) received doses of 200, 400, and 550 mg over 14 days of oral, once daily (QD) dosing. HU6 was well-tolerated at all dose levels. The limit to tolerability was not reached at any of the doses studied in the trial.
“We are highly encouraged by Phase 1 clinical trial results for HU6, which demonstrate a compelling, positive impact on multiple key indicators of cardio-metabolic disorders. The data overwhelmingly support the continued development of HU6 to deliver novel and effective treatment to the millions people who live with poor metabolic health and cardiovascular disease,” said Allen Cunningham, President and CEO of Rivus Pharmaceuticals. “While many existing cardio-metabolic therapies address downstream effects of these diseases, we’ve designed CMAs to address the underlying cause.”
CMAs provide a new, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat and the prevention of additional fat accumulation throughout the body.
The company also announced it has completed enrollment for a double blind, placebo controlled, randomized Phase 2a clinical metabolic study of HU6 in cohorts of participants with high BMI (28-45 kg/m2). Topline data are expected in Q1 2022.
# # #
About Rivus Pharmaceuticals
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease. Rivus’ first-in-class small molecule therapy, HU6, is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body’s natural processes to improve cellular metabolism. Rivus’ therapy presents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of cardio-metabolic conditions, including type 2 diabetes, hypertension, non-alcoholic steatohepatitis (NASH), dyslipidemia and obesity. For more information, please visit rivuspharmadev.wpengine.com.
Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardiometabolic Diseases
NEWS
PRESS RELEASES
Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardiometabolic Diseases
Advancing a pipeline of first-in-class Controlled Metabolic Accelerators (CMAs) to harness the body’s natural processes to improve cellular metabolism and treat the underlying causes of poor metabolic health and cardiovascular disease
Initial programs to focus on type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF)
CHARLOTTESVILLE, Va., July 20, 2021 /PRNewswire/ — Rivus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $35 million Series A financing. Rivus is advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs), designed to improve cellular metabolism and treat the underlying cause of highly-prevalent metabolic and cardiovascular diseases. The round was co-led by Longitude Capital and Medicxi and RxCapital also participated.
“More than 40 million people in the U.S. alone are living with cardio-metabolic disorders, conditions that adversely impact a person’s health and quality of life, as well as place significant cost burdens on healthcare systems. While many existing therapeutic options address the downstream effects of metabolic disease, they do little to address the underlying cause – greater consumption of energy than is required by the body, which over time results in inefficient cellular metabolism and the excess accumulation of fat,” said Allen Cunningham, President and CEO, Rivus Pharmaceuticals. “Our CMAs are designed to effectively target the root cause of these diseases by improving cellular metabolism with the potential to halt the progress of, or even reverse, these diseases.”
CMAs provide a new, measured approach to activating mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat and the prevention of additional fat accumulation throughout the body. Rivus is currently conducting a Phase 2a clinical study with its lead CMA therapeutic, HU6. The Series A financing will enable Rivus to advance a pipeline of CMA therapies to treat a range of metabolic conditions including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with preserved ejection fraction (HFpEF).
“We are very encouraged by early clinical results of HU6 and the potential for CMAs to deliver a new and highly-effective approach to improving metabolic health,” said Patrick Enright, Managing Director at Longitude Capital. “There is tremendous global potential for CMAs to fundamentally change the therapeutic landscape across a variety of difficult to manage chronic diseases related to metabolic health.”
“Rivus has recently completed its Phase 1 program for HU6, and the results exceeded our expectations, demonstrating an early positive impact on key metabolic parameters, while being well-tolerated,” said David Grainger, Ph.D., Chief Scientific Advisor at Medicxi. “Phase 2 studies will provide important insights into HU6’s efficacy in specific metabolic and cardiovascular diseases with this very promising new therapy, and we are excited to advance these programs in partnership with Rivus.”
# # #
About Rivus Pharmaceuticals
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease. Rivus’ first-in-class, small molecule therapy, HU6, is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body’s natural processes to improve cellular metabolism. Rivus’ therapy presents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of cardio-metabolic conditions, including type 2 diabetes, hypertension, non-alcoholic steatohepatitis (NASH), dyslipidemia and obesity. For more information, please visit rivuspharmadev.wpengine.com.
About Longitude Capital
Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit www.longitudecapital.com or LinkedIn.
About Medicxi
Medicxi is an international investment firm with the mission to create and invest in companies across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team and invests in both early stage and late stage therapeutics with a product vision that can fulfill a clear unmet medical need. GlaxoSmithKline, Johnson & Johnson Innovation – JJDC, Inc., Novartis and Verily (an Alphabet company) are investors in Medicxi funds.
Medicxi’s team has been investing in life sciences for over 20 years. Globally, it has invested in 91 innovative biopharma companies and achieved 32 exits through IPO and M&A, including Genmab, PanGenetics (sold to AbbVie), Cellzome (sold to GSK), Micromet (sold to Amgen), Molecular Partners, XO1 (sold to Janssen Pharmaceuticals, Inc.), Minerva Neurosciences, Padlock Therapeutics (sold to Bristol-Myers Squibb), Gadeta (structured transaction with Gilead), Impact BioMedicxines (sold to Celgene) and Adaptive Biotechnologies. Medicxi is also the founding investor of Centessa Pharmaceuticals. Please see https://www.medicxi.com/ for more information.
About RxCapital
RxCapital is the venture capital arm of RxCelerate, a leading international out-sourced drug discovery platform based in Cambridge, UK. RxCapital invests in early-stage biotechnology companies with transformative capability and, unlike many CROs, there is no requirement for portfolio companies to use RxCelerate services. RxCapital will invest in any geography, following an asset-centric investment model, deploying up to £1million per investment. For further information, please contact Nick Tait, Chief Financial Officer of RxCelerate Group: nick@rxcelerate.com.
MEDIA CONTACT
info@rivuspharma.com
